Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: Recommendations from a group of Brazilian f experts;Terapia de reposição enzimática para as mucopolissacaridoses I, II E VI: Recomendações de um grupo de especialistas Brasileiros

Revista da Associacao Medica Brasileira

Volumn 56, Issue 3, 2010, Pages 271-277

  Giugliani, Roberto ^a   Federhen, Andressa ^b   Rojas, Maria Verónica Muñoz ^a   Vieira, Taiane Alves ^a   Artigalás, Osvaldo ^c   Pinto, Louise Lapagesse Carmargo ^b   Azevedo, Ana Cecília ^d   Acosta, Angelina Xavier ^e   Bomfim, Carmem ^f   Lourenço, Charles Marques ^g   Kim, Chong Ae ^g   Horovitz, Dafne ^h   Souza, Denize Bomfim ⁱ   Norato, Denise ^j   Marinho, Diane ^b   Palhares, Durval ^k   Santos, Emerson Santana ^l   Ribeiro, Erlane ^m   Valadares, Eugênia Ribeiro ⁿ   Guarany, Fábio ^b   de Lucca, Gisele Rosone ^o   Pimentel, Helena ^p   de Souza, Isabel Neves ^q   Neto, Jordão Corrêa ^r   Fraga, José Carlos ^a   Góes, José Eduardo ^o   Cabral, José Maria ^s   Simeonato, José ^t   Llerena, Juan Clinton ^h   Jardim, Laura Bannach ^a   Giuliani, Liane de Rosso ^k   da Silva, Luiz Carlos Santana ^q   Santos, Mara ^u   Moreira, Maria Ångela ^b   Kerstenetzky, Marcelo ^v   Ribeiro, Márcia ^w   Ruas, Nicole ^b   Barrios, Patricia ^b   Aranda, Paulo ^x   Honjo, Rachel ^g   Boy, Raquel ^y   Costa, Ronaldo ^b   de Souza, Carolina Fishinger Moura ^z   Alcântara, Flavio F ^aa   Avilla, Sylvio Gilberto A ^ab   Fagondes, Simone ^ac   Martins, Ana Maria ^ad   more..

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c Grupo Hospitalar Conceicao   (Brazil)

^d Médica da Prefeitura Municipal de Gravataí   (Brazil)

^e FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^f FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h INSTITUTO OSWALDO CRUZ   (Brazil)

ⁱ HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^j Faculdade de Medicina da PUC   (Brazil)

^k FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

^l UNIVERSIDADE ESTADUAL DE CIÊNCIAS DA SAÚDE DE ALAGOAS   (Brazil)

^m Faculdade de Medicina de Juazeiro do Norte   (Brazil)

ⁿ FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^o HOSPITAL INFANTIL JOANA DE GUSMÃO   (Brazil)

^p Associacao de Pais e Amigos dos Excepcionais de Sao Paulo   (Brazil)

^q FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^r HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

^s FEDERAL UNIVERSITY OF AMAZONAS   (Brazil)

^t Hospital Infantil   (Brazil)

^u HOSPITAL PEQUENO PRÍNCIPE   (Brazil)

^v HOSPITAL DA RESTAURAÇÃO   (Brazil)

^w FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^x Hosp Evangelico   (Brazil)

^y STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^z Representante da Sociedade Brasileira de Genética Médica   (Brazil)

^aa Sociedade Brasileira de Patologia (SBP)   (Brazil)

^ab Representante da Sociedade Brasileira de Cirurgia Pediátrica   (Brazil)

^ac Representante da Sociedade Brasileira de Pneumologia e Tisiologia   (Brazil)

^ad FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

more..

Author keywords

Enzyme replacement therapy; Glycosaminoglycans V; Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis VI

Indexed keywords

EID: 77955303127     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0104-42302010000300009     Document Type: Article

References (40)

1. Neufeld EF, Muenzer J. The mucopolysaccharidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York (NY): McGraw-Hill Co; 2001. p.3421-52.
2. Ard JL Jr, Bekker A, Frempong-Boadu AK. Anesthesia for na adult with mucopolysaccharidosis I. J Clin Anesth. 2005;17(8):624-6.
3. Leistner S, Giugliani R. A useful routine for the biochemical detection and diagnosis of mucopolysaccharidoses. Genet Molec Biol. 1998;21(1):163-7.
4. Krivit W. Allogeneic stem cell transplantation for the treatment of lyso-somal and peroxisomal metabolic diseases. Springer Semin Immunopathol. 2004;26(1-2):119-32.
5. Lange MC, Teive HA, Troiano AR, Bitencourt M, Funke VA, Setúbal DC, et al. Bone marrow transplantation in patients with storage diseases: a developing country experience. Arq Neuropsiquiatr. 2006;64(1):1-4.
6. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme Replacement Therapy in Mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182-8.
7. Kakkis ED, Schuchman E, He X, Wan Q, Kania S, Wiemelt S, et al. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab. 2001;72(3):199-208.
8. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme Replacement Therapy for Mucopolysaccharidosis I: a Randomized, Double-Blinded, Placebo-Controlled, Multinational Study of Recombinant Human Q-L-Iduronidase (Laronidase). J Pediatr. 2004;144(5):581-8.
9. Harmatz P, Kramer WG, Hopwood JJ, Simon J, Butensky E, Swiedler SJ, Mucopolysaccharidosis VI Study Group. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study. Acta Paediatr Suppl. 2005;94(447):61-8.
10. Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, et al. Direct comparasion of measures of endurance, mobility, and joint function during enzyme-replacement therapy of Mucopolisaccharidosis VI (Maroteaux-Lamy Syndrome): results after 48 weeks in a phase 2 open-labem clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115(6):681-9.
11. Wraith JE. The first 5 years of clinical experience with laroni-dase enzyme replacement therapy for mucopolysacchari -dosis I. Expert Opin Pharmacother. 2005;6(3):489-506.
12. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolisaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465-73.
13. Muenzer J, Guscsavas-Calikoglu M, Shawn E, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacemet therapy in mucopolisaccharidosis II (Hunter Syndrome). Mol Genet Metab. 2007;90(3):329-37.
14. Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90(2):171-80.
15. Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human -L-iduronidase (laronidase). Pediatrics. 2007;120(1):37-46.
16. Clarke LA. Idursulfase for the treatment of mucopolysaccharidosis II. Expert Opin Pharmacother. 2008;9(2):311-17.
17. Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles E, Sa Miranda M, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94(4):469-75.
18. Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123(1):229-40.
19. ®) in patients with mucopolysaccharidosis I. Mol Genet Metabol. 2009;96(1):13-9.
20. Boelens JJ, Wynn RF, O'meara A, Veys P, Bertrand Y, Souillet G, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007;40(3):225-33.
21. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Nat Acad Sci USA. 1990;87(5):1913-6.
22. Biomarin [cited 2009 mar 3]. Biomarin Pharmaceutical Inc. Available from: http://www.bmrn.com/products/aldurazyme.php.
23. Biomarin [cited 2009 mar 9]. Biomarin Pharmaceutical Inc. Available from: http://www.bmrn.com/products/naglazyme.php.
24. Elaprase [cited 2009 mar 3]. Elaprase (idursulfase). Available from; http://www.elaprase.com.
25. FDA. US Food and Drug Administration. Drugs@ FDA. [cited 2009 mar 3]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
26. EMEA. European Medicines Agency. [cited 2009 mar 3]. Available from: http://www.emea.europa.eu.
27. ANVISA. Agência Nacional de Vigilância Sanit́aria. [citado 3 mar 2009]. Dispomvel em: http://www.anvisa.gov.br/.
28. Fuller M, Hopwood JJ, Anson DS. Receptor mediated binding of two glyco-sylation of N-acetylgalactosamine-4-sulphatase. Biochim Biophys Acta. 1998;1406(3):283-90.
29. Auclair D, Hopwood JJ, Brooks DA, Lemontt JF, Crawley AC. Replacement therapy in Mucopolysaccharidosis type VI: advatages of early onset of therapy. Mol Genet Metab. 2003;78(3):163-74.
30. Wraith JE, Scarpa M, Beck M, Bodamer AO, De Meirleir L, Guffon N, Lund AM, Malm G, Vand der Ploeg A, Zeman J. Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr.
31. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysac-charidosis VI. Pediatrics, 2007; 120 (2):405-18.
32. Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles E, Sá Miranda M, MPS VI Phase 3 Study Group. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-bind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148(4):533-9.
33. McGill JJ, Inwood AC, Coman DJ, Lipke ML, Skinner J, Morris B. Enzyme replacement therapy for MPS VI with recombinant human N-acetygalactos-amine 4-sulfatase (rhASB) from 8 weeks of age - a sibling control study. J Inher Metab Dis. 2006; 29: Suppl 1: 65.
34. Anbu A, Mercer J, Wraith JE. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. J Inherit Metab Dis. 2006;29:230-1.
35. Wegrzyn G, Tylki-Szymanska A, Keberek A, COMPLETAR. Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy. Am J Med Genet Part A. 2007;143A:1925-7.
36. Kim KH, Decker C, Burton BK. Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arysulfatase B (galsulfase [Naglazyme]).Pediatrics. 2008;12(3):714-7.
37. Muñoz-Rojas MV, Vieira T, Costa R, Fagondes S, John A, Jardim LB et al. Intrathecal enzyme replacement therapy in a patient with mucopolysac-charidosis type I and symptomatic cord compression. Am J Med Genet. 2008:146A:2538-44.
38. Cox-Brikman J, Timmermans RGM, Wijbrug FA, Donker WE, van de Ploeg AT, Aerts JM et al. Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe. J Inherit Metab Dis. 2007; 30(6):984. Epub 2007 sep 21.
39. Pereira VG, Matins AM, Micheletti C, COMPLETAR. Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy. Clin Chim Acta. 2008;387(1-2):75-9.
40. Randall DR, Sinclair GB, Colobong KE, Hetty E, Clarke LA. Heparin Cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol Genet Metab. 2006;88(3):235-43.